Equities

Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)112.40
  • Today's Change1.90 / 1.71%
  • Shares traded119.04k
  • 1 Year change+34.17%
  • Beta0.7280
Data delayed at least 15 minutes, as of Nov 22 2024 15:32 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy8
Outperform15
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 22 analysts offering 12 month price targets for Sarepta Therapeutics Inc have a median target of 198.50, with a high estimate of 219.00 and a low estimate of 147.12. The median estimate represents a 79.64% increase from the last price of 110.50.
High98.2%219.00
Med79.6%198.50
Low33.1%147.12

Earnings history & estimates in USD

On Nov 06, 2024, Sarepta Therapeutics Inc reported 3rd quarter 2024 earnings of 0.34 per share. This result exceeded the -0.13 consensus loss of the 14 analysts covering the company and outperformed last year's 3rd quarter results by 0.80.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate+94.45%
Sarepta Therapeutics Inc reported annual 2023 losses of -5.80 per share on Feb 28, 2024.
Average growth rate+6.55%
More ▼

Revenue history & estimates in USD

Sarepta Therapeutics, Inc. had 3rd quarter 2024 revenues of 467.17m. This bettered the 409.30m consensus of the 18 analysts covering the company. This was 84.29% above the prior year's 3rd quarter results.
Average growth rate+10.07%
Sarepta Therapeutics, Inc. had revenues for the full year 2023 of 1.24bn. This was 33.26% above the prior year's results.
Average growth rate+34.49%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.